Cosentyx (secukinumab) - Novartis
Cosentyx: Data from P3 EXCEED trial (NCT02745080) for psoriatic arthritis in 2019/2020 (Novartis) - May 25, 2019 - Investor Event: Data from P3 SURPASS trial (NCT03259074) for ankylosing spondylitis in 2022 
P3 data
https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-novartis-management-presentation.pdf
 
May 25, 2019
 
 
46e8df25-4668-49d0-89c7-c16091c4fe8b.jpg